NCT06022874

Brief Summary

The goal of this observational study is to learn about the potential therapeutic effects of topical CBD products produced by Phoilex Ltd., specifically the Releaf Gel, in those diagnosed with atopic dermatitis. Patients will be routinely assessed via questionnaire, and physical measurements will be taken with respect to the affected area studied in order to judge clinical efficacy. The main question\[s\] it aims to answer are:

  • Did you experience an immediate increase in skin hydration?
  • Did you experience a soothing or comforting feeling on your irritated skin area? Please explain where your affected area is located, and also include at what time point this occurred. Example: Affected Area: Palm, Time Point: 1-hour post-application
  • Upon the affected area being in the healing phase, was your skin itch/scratch free for 4/6/10/12 hours (please circle)?
  • Did you experience immediate relief from your skin inflammation?
  • Did the study cream absorb quickly into your skin, without any greasy feeling?
  • Has your skin flare disappeared in 2 week(s)?
  • Has your skin condition appearance improved? (Yes/No) Participants will apply Phoilex Releaf Gel (a cream) to their affected areas of atopic dermatitis. The questions listed above shall be discussed and observations recorded at the 0 week, 1 week, 2 week, and 4 week time points. Additional monitoring questions may be asked of the participants to ensure the safety of the product. A chart will be provided to the participants to track Phoilex Releaf Gel usage (how many pumps, and time of day) throughout duration of the study. We hypothesize that Releaf gel will be suitable to ameliorate the common signs and symptoms of atopic dermatitis as well as improve patient quality of life.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 15, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 28, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 5, 2023

Completed
25 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2023

Completed
Last Updated

September 5, 2023

Status Verified

August 1, 2023

Enrollment Period

3 months

First QC Date

August 28, 2023

Last Update Submit

August 28, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Will topically applied CBD be effective in reducing the appearance/clearing of atopic dermatitis after 4 weeks of study treatment?

    Outcome will be measured based on observations recorded at 0 weeks, 1 week, 2 week, and 4 week time point, not limited to physical assessment, clinical photography, and the responses of questions below: * Did you experience an immediate increase in skin hydration? * Did you experience a soothing or comforting feeling on your irritated skin area? Please explain where your affected area is located, and also include at what time point this occurred. Example: Affected Area: Palm, Time Point: 1-hour post-application * Upon the affected area being in the healing phase, was your skin itch/scratch free for 4/6/10/12 hours (please circle)? * Did you experience immediate relief from your skin inflammation? * Did the study cream absorb quickly into your skin, without any greasy feeling? * Has your skin flare disappeared in 2 week(s)? * Has your skin condition appearance improved? (Yes/No)

    5 weeks

Study Arms (1)

Patient's Diagnosed with Atopic Dermatitis

Patient's Diagnosed with Atopic Dermatitis

Other: Phoilex Releaf Gel

Interventions

Patients will be given the Releaf Gel to apply to the affected areas daily. They will be examined at the following time points: Immediately after application, 1 week, 2 weeks, and 4 weeks. The instructions given to the patient shall be to apply one pump per every affected area, wash hands before applying to affected area, apply twice a day (morning, and evening), apply on clean skin, and application after showering is advised. The number of pumps of Phoilex Releaf gel will be documented within a chart provided to the patient. It is suggested that not more than 25 lesions compassing an area greater than 50 cm² in total be treated during the course of this study. The maximum dose would be 240 mL of Phoilex Releaf gel in 30 days. The minimum dose would be 0.5 mL (one pump) of the Phoilex Releaf gel in 30 days. The maximum daily dose of CBD per day 46 mg per application, equivalent to 92 mg per day.

Patient's Diagnosed with Atopic Dermatitis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with moderate to severe atopic dermatitis will be selected and recruited from medical clinics, social media, as well as invitation should they meet the inclusion criteria. Participants must be able to travel to clinic location in Brampton.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Phoenix Medical Spa X Peak Human

Brampton, Ontario, L6W 3E1, Canada

RECRUITING

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Sanjeev Goel, MD

    Phoenix Medical Spa X Peak Human

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sanjeev Goel, MD

CONTACT

Sarina Pilaroscia

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 28, 2023

First Posted

September 5, 2023

Study Start

July 15, 2023

Primary Completion

September 30, 2023

Study Completion

October 30, 2023

Last Updated

September 5, 2023

Record last verified: 2023-08

Locations